Beta Drugs Ltd (NSE: BETA) is a Panchkula, Haryana-based company in the Medicinal Chemicals and Botanical Products industry. With a market capitalisation of ₹1,807 Cr, it ranks #1,283 by market cap among the 6,137 Indian listed companies on FinBizNet, and #39 of 86 in Medicinal Chemicals and Botanical Products. At ₹1,894.60 (as of 25 Oct 2026), the share price is 32.5% below its 52-week high of ₹2,807.90 and 91.4% above its 52-week low of ₹990.10. The share price is up 8.4% over one year and down 18.2% over three months.
| Current Price | ₹1,894.60 |
|---|---|
| Market Cap | ₹1,807 Cr |
| NSE Symbol | BETA |
| Sector | Health Care > Pharmaceuticals, Biotechnology and Life Sciences > Pharmaceuticals |
| Sub-Industry | Biotechnology and Life Sciences > Medicinal Chemicals and Botanical Products |
| P/E Ratio | 42.1 |
| Return on Equity | 18.78% |
| Return on Assets | 7.85% |
| 52-Week Range | ₹990.10 – ₹2,807.90 |
| 1-Year Price Change | +8.4% |
| 3-Month Price Change | -18.2% |
| Beta (1Y) | 0.19 |
| Headquarters | Panchkula, Haryana |
| Website | betadrugslimited.com |
| Revenue | ₹137 Cr |
|---|---|
| Net Profit | ₹19 Cr |
| Net Margin | 14.0% |
| EPS (Basic) | ₹16.59 |
| Basis | consolidated |
Figures in ₹ crore, parsed from the company's exchange filing (XBRL).
Beta Drugs Limited develops, manufactures, and sells anti-cancer bulk drugs and finished dosages in India. The company offers cosmeceutical and oncology products. It also manufactures active pharmaceutical ingredients (API) and pharmaceutical formulation intermediates (PFI). The company exports its products. Beta Drugs Limited was founded in 1985 and is based in Panchkula, India.
1. Manufacturing of Oncology Medicines-This segment develops, manufactures, and trades in oncology medicines.
1. Trading and Manufacturing of Pharmaceutical Products-100%
| Company | Market Cap | P/E | ROE | Latest Qtr Revenue | 1Y Change |
|---|---|---|---|---|---|
| Sun Pharmaceutical Industries Limited | ₹4,21,995 Cr | 36.4 | 14.72% | ₹15,300 Cr | +5.4% |
| Zydus Lifesciences Ltd | ₹1,12,020 Cr | 22.2 | 18.32% | ₹8,017 Cr | +14.7% |
| Laurus Labs Ltd | ₹1,11,310 Cr | 125.3 | 17.74% | ₹2,026 Cr | +125.7% |
| Cipla Limited | ₹1,07,048 Cr | 27.6 | 11.74% | ₹7,119 Cr | -14.7% |
| Dr.Reddys Lab | ₹1,02,611 Cr | 24.1 | 11.52% | ₹8,698 Cr | -0.9% |
| Aurobindo Pharma Ltd. | ₹95,910 Cr | 26.8 | 9.93% | ₹9,150 Cr | +41.7% |
| Mankind Pharma | ₹93,977 Cr | 48.7 | 12.45% | ₹4,031 Cr | -9.9% |
| Lupin Ltd | ₹89,426 Cr | 16.6 | 26.91% | ₹8,277 Cr | -1.1% |
| Beta Drugs Ltd | ₹1,807 Cr | 42.1 | 18.78% | ₹137 Cr | +8.4% |
Listed by market capitalisation. Ratios are shown for context only.
Beta Drugs Ltd is trading at ₹1,894.60, with a market capitalisation of ₹1,807 Cr.
Beta Drugs Ltd operates in the Health Care > Pharmaceuticals, Biotechnology and Life Sciences > Pharmaceuticals space (Biotechnology and Life Sciences > Medicinal Chemicals and Botanical Products).
Beta Drugs Ltd has a P/E of 42.1 and a return on equity of 18.78%.
Beta Drugs Ltd is listed on the NSE under the symbol BETA.
Beta Drugs Ltd's share price is up 8.4% over one year and down 18.2% over three months. Its 52-week range is ₹990.10 to ₹2,807.90.
In Q2 FY27, Beta Drugs Ltd reported revenue of ₹137 Cr and net profit of ₹19 Cr, with basic EPS of ₹16.59 (consolidated, parsed from the company's exchange filing).
Data as of 25 Oct 2026. Descriptive market data only — not investment advice.